Thu, Dec 25, 2014, 2:36 AM EST - U.S. Markets closed for Christmas


% | $
Quotes you view appear here for quick access.

ImmunoGen, Inc. Message Board

  • bioimmunomabman bioimmunomabman Aug 14, 2013 10:26 AM Flag

    Junius needs to deliver!!!

    No doubt he is feeling some heat after the recent decline. If he goes on Cramer and has nothing new, just more of the same, today's gains will fade fast and he will be back on the hot seat. This move is speculation that there is something new. Also, the stock is waaay oversold and that's likely due to a ton of new shorting since $20+. What happened next was a strong press release followed by a terrible cc performance then insider sales. Cramer should ask him why why should people buy when he is always selling his stock. Cramer may be irritated at Junius by now, he comes on the show, makes rosy predictions and then can't back them up.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Bio, I know you are not a fan of Dan. However, this last decline had nothing to do with him. If you've received stock options as every CEO does, you know that you can't save them all for one event or the day before they expire. Everyone has different tax strategies and personal needs. He did give the shorts like Cantor & Guggenheim some fodder for selling by highlighting insider sells. However, the last earnings exceeded expectations!

      Sentiment: Strong Buy

    • To be fair, I don't think Junius made and rosy predictions on Cramer's show. What I suspect Cramer wants to discuss is the approval of Kadcyla, when he was last on the show that had not happened yet. I would expect Junius to give a brief update on the pipeline as well. Not much more than what was in the last earnings call. What would be a completely fair question to ask is how they see funding their pipeline and the ambitious clinical trials and clinical infrastructure they talked about in that conference call. Does funding any of that lead to another stock offering? He should be very prepared to answer that with a polished response.

      Chinese Hamsters

      • 1 Reply to chinesehamsters
      • the last cc was an abomination. Junius usually sounds OK until someone with knowledge (analysts) ask questions and dig a little deeper. I would rather hear John Lambert come on and talk about the science, the technology/platform, that would be interesting. Junius rarely has anything of interest to say, probably because they can't successfully design, or complete a clinical study past phase I. The only positive thing I heard on the last call was the CFO backing away from any talk of monetizing Kadcyla royalties. If they start talking about that again, I am out. All I want to hear is either all options are on the table, or we have made clinical progress, or we have formed a new partnership. Anything else is just talk.

    • management in many companies sell for different reasons! I think this is the last dip, before moving over its 52 week high and beyond. Shorts soon will not be a factor holding this down.

      Sentiment: Strong Buy

5.90+0.13(+2.25%)Dec 24 1:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.